Fig. 1From: Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation studyCONSORT diagram of patient disposition and flow through the studyBack to article page